-

ABIONYX Pharma Announces Its Financial Calendar for the Year 2026

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.

Events

Dates*

Cash position and activity update for Q4 2025

Thursday, February 26, 2026

2025 Full-Year Results

Thursday, March 12, 2026

Cash position and activity update for Q1 2026

Thursday, May 28, 2026

Cash position and activity update for Q2 2026

Thursday, August 27, 2026

2026 Half-Year Results

Thursday, September 24, 2026

Cash position and activity update for Q3 2026

Thursday, November 26, 2026

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

Contacts

ABIONYX Pharma
infos@abionyx.com

ABIONYX Pharma

BOURSE:ABNX
Release Versions
EnglishFrench

Contacts

ABIONYX Pharma
infos@abionyx.com

More News From ABIONYX Pharma

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) (“Abionyx” or the “Company”), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces the success of its capital increase with preferential subscription rights (the “Rights Issue”), launched on May 27, 2026, which has been subscribed at 100% after part...

ABIONYX Pharma : Combined Annual Shareholders’ Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:  ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, hereby notifies the public that the Company’s Combined Annual General Meeting will be held on Tuesday, June 30, 2026, at 4:00 p.m., at the Company’s registered office, 33-43 Av. Georges Pompidou, 31130 Balma, Fra...

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) May 31, 2026 35,511,655 45,235,782 44,979,557 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of a...
Back to Newsroom